Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 08 May 2012 | By Alexander Gaffney, RAC
Pharmaceutical manufacturer Abbott Laboratories has agreed to pay a near-record $1.5 billion in fines for the off-label promotion of its anti-seizure drug Depakote, with the total to be split between the federal government, states and consumers.
In a lengthy statement released by the Department of Justice (DOJ), Deputy Attorney General James M. Cole called the settlement a "strong message to other companies" not to engage in fraud.
DOJ explained in its statement that Abbott executives had agreed to market Depakote for a wide range of indications not approved by the US Food and Drug Administration (FDA).
"In an agreed statement of facts filed in the criminal action, Abbott admits that from 1998 through 2006, the company maintained a specialized sales force trained to market Depakote in nursing homes for the control of agitation and aggression in elderly dementia patients, despite the absence of credible scientific evidence that Depakote was safe and effective for that use," wrote DOJ in their statement. "In addition, from 2001 through 2006, the company marketed Depakote in combination with atypical antipsychotic drugs to treat schizophrenia, even after its clinical trials failed to demonstrate that adding Depakote was any more effective than an atypical antipsychotic alone for that use."
As part of the agreement, Abbott will be subject to a corporate integrity agreement (CIA) to ensure the company remains in compliance.
"The five-year CIA requires, among other things, that Abbott's board of directors review the effectiveness of the company's compliance program, that high-level executives certify to compliance, that Abbott maintain standardized risk assessment and mitigation processes, and that the company post on its website information about payments to doctors," explained DOJ. Failure to comply with the CIA will subject Abbott to the possibility of being excluded from federal programs, including Medicare and Medicaid.
The settlement is reportedly one of the largest ever, behind only Pfizer's $2.3 billion fine for marketing Bextra and GlaxoSmithKline's $3 billion settlement over its marketing of Avandia, reports The New York Times.
DOJ - Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil Investigations of Off-label Promotion of Depakote
DOJ - Acting Associate Attorney General Tony West Speaks at Press Conference Regarding Settlement with Abbott Laboratories
The New York Times - Abbott Settles Marketing Lawsuit
NPR - Abbott Labs To Pay $1.5B Over Anti-Seizure Drug
Modern Healthcare - Abbott to pay $1.5 billion settlement
Thompson Reuters - Abbott Depakote Settlement Totals $1.5 Billion
NASDAQ - 2nd UPDATE: Abbott To Pay $1.6 Billion To Settle Depakote Marketing Probes
Pharmalot - Abbott To Pay $1.6 Billion To Settle Depakote Probes
$1.5B Abbott fine proves Feds serious about penalizing off-label promotion
Pharma Times - Abbott pays $1.6 billion to settle Depakote investigation
Tags: Corporate Integrity Agreement, CIA, Anti-Seizure, $1.5 billion, Depakote, Abbott, Fine, Off-label, Latest News, marketing
Regulatory Focus newsletters
All the biggest regulatory news and happenings.